Protalix BioTherapeutics, Inc.: 10-Q filed 2025-11-13
What Protalix BioTherapeutics, Inc. reported in its quarterly report filed 2025-11-13 (fiscal Q3 2025): 41 published measures, 116 facts as tagged in accession 0001104659-25-110824.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-11-13
- Fiscal period
- fiscal Q3 2025
- Accession
- 0001104659-25-110824 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Protalix BioTherapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 82,264,000 | USD | |
| At 2024-12-31 | 73,417,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 29,356,000 | USD | |
| At 2024-12-31 | 30,206,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 52,908,000 | USD | |
| At 2025-06-30 | 49,903,000 | USD | |
| At 2024-12-31 | 43,211,000 | USD | |
| At 2024-09-30 | 32,437,000 | USD | |
| At 2024-06-30 | 28,581,000 | USD | |
| At 2023-12-31 | 33,569,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 13,647,000 | USD | |
| At 2024-12-31 | 19,760,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 2,355,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -1,100,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 3,236,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -3,562,000 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -14,023,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 4,683,000 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 1,235,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 857,000 | USD | 274 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 17,851,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 43,622,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 17,959,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 35,181,000 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 9,180,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -20,420,000 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -1,254,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 19,541,000 | USD | 274 |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 79,281,685 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 78,225,112 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 73,549,745 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 73,301,091 | shares | 274 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 80,814,564 | shares | 92 |
| 2025-01-01 to 2025-09-30 | 78,225,112 | shares | 273 |
| 2024-07-01 to 2024-09-30 | 81,217,068 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 73,301,091 | shares | 274 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 0.03 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | -0.01 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | 0.04 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -0.05 | USD/shares | 274 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 0.03 | USD/shares | 92 |
| 2025-01-01 to 2025-09-30 | -0.01 | USD/shares | 273 |
| 2024-07-01 to 2024-09-30 | 0.03 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -0.05 | USD/shares | 274 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -116,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 268,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 607,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 400,000 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 4,724,000 | USD | |
| At 2024-12-31 | 4,591,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 1,565,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 2,599,000 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 2,131,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -842,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 3,991,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -3,292,000 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 66,502,000 | USD | |
| At 2024-12-31 | 60,078,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 21,945,000 | USD | |
| At 2024-12-31 | 25,621,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 14,425,000 | USD | |
| At 2024-12-31 | 2,909,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 21,255,000 | USD | |
| At 2024-12-31 | 21,243,000 | USD |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 8,324,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 22,374,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 8,375,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 20,433,000 | USD | 274 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 2,929,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 8,156,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 2,595,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 9,194,000 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 4,467,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 13,934,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 2,998,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 8,846,000 | USD | 274 |
Cash including restricted cash
Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 13,647,000 | USD | |
| At 2024-12-31 | 19,760,000 | USD | |
| At 2024-09-30 | 27,409,000 | USD | |
| At 2023-12-31 | 23,634,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 7,810,000 | USD | |
| At 2024-12-31 | 5,430,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 8,177,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-09-30 | 8,126,000 | USD | |
| At 2024-12-31 | 9,568,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 2,239,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | -832,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 3,843,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -3,162,000 | USD | 274 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | -1,100,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -3,562,000 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 1,078,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | 970,000 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 108,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 10,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | -148,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 130,000 | USD | 274 |
Current income tax expense or benefit
Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | -175,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 91,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 164,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 164,000 | USD | 274 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 59,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 177,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 443,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 236,000 | USD | 274 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | 1,532,000 | USD | 274 |
Income taxes paid, net
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 1,182,000 | USD | 273 |
Proceeds from issuing common stock
Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 6,812,000 | USD | 273 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-07-01 to 2025-09-30 | 457,000 | USD | 92 |
| 2025-01-01 to 2025-09-30 | 1,338,000 | USD | 273 |
| 2024-07-01 to 2024-09-30 | 413,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 1,207,000 | USD | 274 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 11,768,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -3,069,000 | USD | 274 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-09-30 | 12,000 | USD | 273 |
| 2024-01-01 to 2024-09-30 | -1,846,000 | USD | 274 |
Inspect the source
- Entity
- Protalix BioTherapeutics, Inc. / CIK 0001006281
- Captured
- 2026-09-20T05:12:00.706Z
- SEC response SHA-256
5022eb9c9008f3ac21090b4bd34c0341e843ccbd807493dfa2a9e5fc19632a16
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001006281.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))